CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
NU6140
CAS:<p>NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).</p>Fórmula:C23H30N6O2Pureza:98.33%Forma y color:SolidPeso molecular:422.52CDK4/6-IN-2
CAS:<p>CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。</p>Fórmula:C27H32F2N8Pureza:99.47%Forma y color:SolidPeso molecular:506.59Trilaciclib hydrochloride
CAS:<p>Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).</p>Fórmula:C24H32Cl2N8OPureza:99.69% - 99.89%Forma y color:SolidPeso molecular:519.47Nimbolide
CAS:<p>Nimbolide, from neem, inhibits CDK4/6, NF-κB, Wnt, PI3K-Akt, MAPK, JAK-STAT pathways and induces apoptosis.</p>Fórmula:C27H30O7Pureza:95.84% - 99.4%Forma y color:SolidPeso molecular:466.52hSMG-1 inhibitor 11j
CAS:<p>hSMG-1 inhibitor 11j: pyrimidine, IC50=0.11 nM, >455x selective vs. mTOR/PI3Kα/γ/CDK1/CDK2; cancer research use.</p>Fórmula:C27H28ClN7O3SPureza:99.22% - 99.65%Forma y color:SolidPeso molecular:566.07NVP-2
CAS:<p>NVP-2 selectively inhibits CDK9 (IC50: 0.514 nM), prompts apoptosis, and affects other CDKs (IC50: 0.584-0.706 μM).</p>Fórmula:C27H37ClN6O2Pureza:99.13%Forma y color:SolidPeso molecular:513.07Garcinone C
CAS:<p>Garcinone C, a xanthone from Garcinia oblongifolia, is anti-inflammatory, promotes healing, and may fight some cancers.</p>Fórmula:C23H26O7Pureza:99.13% - 99.92%Forma y color:SolidPeso molecular:414.45(R)-CR8
CAS:<p>(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.</p>Fórmula:C24H29N7OPureza:98.41%Forma y color:SolidPeso molecular:431.53Lerociclib dihydrochloride
CAS:<p>Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/</p>Fórmula:C26H36Cl2N8OPureza:97.4%Forma y color:SolidPeso molecular:547.52Simurosertib
CAS:<p>Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).</p>Fórmula:C17H19N5OSPureza:99.93% - 99.93%Forma y color:SolidPeso molecular:341.43CDKI-73
CAS:<p>CDKI-73: strong CDK9 blocker, Ki 4 nM, kills CLL cells selectively, aids cisplatin.</p>Fórmula:C15H15FN6O2S2Pureza:98.11%Forma y color:SolidPeso molecular:394.45BRD6989
CAS:<p>BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.</p>Fórmula:C16H16N4Pureza:99.43%Forma y color:SolidPeso molecular:264.33CDK2-IN-4
CAS:<p>CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.</p>Fórmula:C23H18N6O2SPureza:97.24% - 99.10%Forma y color:SolidPeso molecular:442.49Avotaciclib
CAS:<p>Avotaciclib (BEY1107) is a potent and orally active cyclin dependent kinase 1 (CDK1) inhibitor.Avotaciclib can be used to study locally advanced or metastatic</p>Fórmula:C13H11N7OPureza:98.02%Forma y color:SolidPeso molecular:281.27Cyclin K degrader 1
<p>Cyclin K degrader 1 is a Cyclin K degrader.Cyclin K degrader 1 is a degrader converted from AT-7519.Cyclin K degrader 1 has weak degrading activity against Cyclin K but does not result in a sustained decrease in degradation affinity.Cyclin K degrader 1 is a degrader converted from AT-7519.</p>Fórmula:C23H17Cl2N5O2Pureza:99.76%Forma y color:SolidPeso molecular:466.32(±)-Enitociclib
CAS:<p>(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.</p>Fórmula:C19H18F2N4O2SPureza:99.29%Forma y color:SolidPeso molecular:404.43Samuraciclib hydrochloride
CAS:<p>Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).</p>Fórmula:C22H31ClN6OPureza:98.99% - 99.8%Forma y color:SolidPeso molecular:430.97Ribociclib succinate
CAS:<p>Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Fórmula:C27H36N8O5Pureza:99.9%Forma y color:SolidPeso molecular:552.63MBQ-167
CAS:<p>MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).</p>Fórmula:C22H18N4Pureza:98.07% - 99.52%Forma y color:SolidPeso molecular:338.41Amantadine hydrochloride
CAS:<p>Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.</p>Fórmula:C10H18ClNPureza:99.98%Forma y color:Solid CrystallinePeso molecular:187.71XPW1
CAS:<p>XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.</p>Fórmula:C36H39ClFN7O2Pureza:98.08%Forma y color:SoildPeso molecular:656.19Cirtuvivint
CAS:<p>Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.</p>Fórmula:C24H25N7OPureza:99.46% - >99.99%Forma y color:SolidPeso molecular:427.5Ca2+ channel agonist 1
CAS:<p>Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.</p>Fórmula:C19H26N6OPureza:97.71%Forma y color:SolidPeso molecular:354.45CDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Fórmula:C20H21F2N9Forma y color:SolidPeso molecular:425.448(E/Z)-THZ1 2HCl
CAS:<p>THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.</p>Fórmula:C31H30Cl3N7O2Pureza:99.51%Forma y color:SolidPeso molecular:638.98[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Fórmula:C98H138F3N21O39Pureza:98%Forma y color:SolidPeso molecular:2291.25EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Fórmula:C30H20N6OSPureza:98%Forma y color:SolidPeso molecular:512.58FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:Liquid(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Forma y color:SolidPeso molecular:513.38PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Fórmula:C43H51FN12O7Forma y color:SolidPeso molecular:866.94BSJ-03-204
CAS:<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Fórmula:C43H48N10O8Forma y color:SolidPeso molecular:832.9dCeMM3
CAS:<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Fórmula:C14H11ClN4OSPureza:98.48% - 99.41%Forma y color:SolidPeso molecular:318.78JH-XI-10-02
CAS:<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161CDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Fórmula:C19H27N7OForma y color:SolidPeso molecular:369.464CDK4/6-IN-5
CAS:<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Fórmula:C22H28ClFN6O4SForma y color:SolidPeso molecular:527.01CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Fórmula:C32H34FN7O4Forma y color:SolidPeso molecular:599.655BLINK15
<p>BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.</p>Forma y color:Odour SolidCDK5-IN-1
CAS:<p>CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.</p>Fórmula:C24H25FN6O3SForma y color:SolidPeso molecular:496.56CDK12/13-IN-2
<p>CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.</p>Fórmula:C24H22FN7O2Forma y color:SolidPeso molecular:459.48BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Forma y color:LiquidJH-XVI-178
CAS:<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Fórmula:C22H22ClN7OForma y color:SolidPeso molecular:435.92CDK9 inhibitor HH1
CAS:<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Fórmula:C13H15N3OSPureza:99.92%Forma y color:SolidPeso molecular:261.34IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Fórmula:C23H32FN5O2SiForma y color:SolidPeso molecular:457.625CDK2/PIM1-IN-1
<p>CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.</p>Forma y color:Odour SolidLL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Fórmula:C37H43N5OForma y color:SolidPeso molecular:573.77PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Fórmula:C43H56N10O5Forma y color:SolidPeso molecular:792.97EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Fórmula:C49H32N12O2S2Pureza:98%Forma y color:SolidPeso molecular:884.99CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Fórmula:C20H20BrF3N6O2Forma y color:SolidPeso molecular:513.319EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Fórmula:C24H16N6OS2Pureza:98%Forma y color:SolidPeso molecular:468.55Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Pureza:98%Forma y color:Odour Solid
